Table S2 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Year: 2023
Type: other
Abstract: Treatment-related Adverse Events by CTCAE Grade and MedDRA System Organ Class and Preferred Term
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361938173
